Regulatory Approvals, Ongoing Clinical Trials, Divestures, New Borrowings and Regulatory Applications - Research Report on Zoetis, GSK, Actavis, Kindred Healthcare, TESARO

NEW YORK, August 8, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Zoetis Inc. (NYSE: ZTS), GlaxoSmithKline plc (ADR) (NYSE: GSK), Actavis Inc. (NYSE: ACT), Kindred Healthcare, Inc. (NYSE: KND), and TESARO Inc. (NASDAQ: TSRO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Zoetis Inc. Research Report

On August 4, 2013, Zoetis Inc. (Zoetis) announced that its joint venture in China has received an approval by the Ministry of Agriculture of the People's Republic of China for Rui Lan An, a specialized vaccine that helps control the highly pathogenic porcine reproductive and respiratory syndrome (HP PRRS). The Company informed that Rui Lan An, which is the first vaccine from the joint venture that was entered in order to develop and manufacture animal vaccines designed to meet the needs of China's livestock producers, will be launched later in August 2013. Stefan Weiskopf, Executive Vice President and President, Asia Pacific Region at Zoetis, said, "Rui Lan An exemplifies the commitment of our joint venture to develop and manufacture quality vaccines well matched to the local health challenges facing China's pork industry." The Full Research Report on Zoetis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/ZTS]

--

GlaxoSmithKline plc (ADR) Research Report

On August 2, 2013, GlaxoSmithKline plc (GSK) announced that the U.S. Prescription Drug User Fee Act (PDUFA) goal date for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes, was extended by three months to April 15, 2014 to provide ample time for a full review of information submitted by GSK in response to the Food and Drug Administration (FDA)'s requests. GSK stated that it has submitted a Biologics License Application to the US FDA for albiglutide on January 14, 2013, followed by the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency on March 7, 2013. The Company also informed that the EMA filing is progressing according to schedule. The Full Research Report on GlaxoSmithKline plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/GSK]

--

Actavis Inc. Research Report

On August 2, 2013, Actavis, Inc. (Actavis) announced that Actavis Limited, Bank of America N.A. (as Administrative Agent) and a syndicate of banks participating as lenders have entered into a new senior unsecured term loan credit and guaranty agreement, under which the lenders to the agreement will provide loans to certain entities of Warner Chilcott plc (Warner Chilcott) in an aggregate amount not exceeding $2 billion and comprising of a $1 billion three-year Tranche and a $1 billion five-year Tranche. Actavis said that the proceeds from borrowings will be used to finance the repayment of existing credit facilities of the WC Borrowers and pay transaction fees and expenses. In addition, Actavis stated that the Company, Bank of America, N.A., and a syndicate of banks participating as lenders have agreed to amend and restate Actavis' existing $750 million senior unsecured revolving credit loan facility dated as of September 16, 2011, and also to amend and restate Actavis' existing $1.8 billion senior unsecured term loan credit facility dated June 22, 2012.The Full Research Report on Actavis Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/ACT]

--

Kindred Healthcare, Inc. Research Report

On August 5, 2013, Kindred Healthcare Inc. (Kindred Healthcare) reported its Q2 2013 financial results. The Company reported a decline in revenues of 1% YoY to $1.4 billion. Net income was $1.7 million or $0.03 per diluted share, compared to net income of $15.5 million or $0.29 per diluted share in Q2 2012. Commenting on the results, Paul J. Diaz, Kindred Healthcare CEO said, "Despite significant reimbursement pressures brought on by federal sequestration cuts of 2% beginning April 1, Kindred reported solid second quarter core results." He added, "In addition, we are continuing to see the benefits of the Ventas nursing center transition to our continuing operations. The disposition of these 54 nursing centers lifted our earnings from continuing operations by $0.11 per diluted share in the first half of 2013." The Full Research Report on Kindred Healthcare, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-05/KND]

--

TESARO Inc. Research Report

On July 25, 2013, TESARO Inc. (TESARO) reported its Q2 2013 financial results. Research and development expenses increased 57.6% YoY to $18.2 million. Net loss was $21.6 million or $0.67 per diluted share in Q2 2013, compared to net loss of $20.2 million or $21.31 per diluted share in Q2 2012. Commenting on the quarter's performance, Lonnie Moulder, CEO of TESARO, said, "TESARO is well positioned to meet several significant milestones in the second half of this year. We plan to report top-line results from the rolapitant pivotal program by year end, and we remain on track to begin enrollment in a Phase 3 study of niraparib in patients with BRCA-positive breast cancer. In addition, we look forward to continued enrollment in our Phase 3 trial of niraparib for ovarian cancer and to the first presentation of TSR-011 clinical data in September." The Full Research Report on TESARO Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-08-06/TSRO]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports